Eton Pharmaceuticals Welcomes New Chief Commercial Officer
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) is excited to announce the appointment of Ipek Erdogan-Trinkaus as its new Chief Commercial Officer (CCO). Known for her extensive leadership in the commercial sector of the pharmaceutical industry, Ms. Erdogan-Trinkaus arrives with vast experience that spans both larger entities and startups, providing a comprehensive insight into effective sales and marketing strategies.
Experience in Pediatric Endocrinology
Ms. Erdogan-Trinkaus has a strong background specifically in pediatric endocrinology, making her a strategic addition to the company as Eton continues to expand its portfolio targeting rare diseases. Her previous role at Tolmar Pharmaceuticals saw her directing impactful marketing campaigns, notably for their pediatric product, FENSOLVI. Such robust experience will serve Eton well as they gear up for exciting product launches.
Anticipated Product Launches
Sean Brynjelsen, CEO of Eton Pharmaceuticals, expressed enthusiasm about Ms. Erdogan-Trinkaus joining the team, particularly during this pivotal period. "With major milestones ahead, including the anticipated closing of Increlex and the launch of ET-400, I am confident that her expertise will greatly contribute to our growth phase," he noted. Eton's management looks forward to having her insights guide the impending launches and future projects.
A Commitment to Innovation in Healthcare
Ms. Erdogan-Trinkaus is passionate about fostering innovation that significantly impacts patient care. She expressed her eagerness to join Eton, stating, "Eton has an amazing foundation of commercial skills and a dedicated team ready to make a difference for patients facing rare diseases. Together, we will work on the upcoming launches and broaden our impact in the industry." Her strong commitment to advancing healthcare through innovative treatments aligns perfectly with Eton's mission.
Background and Education
Her career path showcases dedication not only in pharmaceuticals but also in the food and beverage industry, where she previously served as the Chief Commercial Officer for a prominent plant-based brand. With educational qualifications including a Bachelor of Science in Business Administration from Middle East Technical University and an MBA from The Ohio State University's Fisher College of Business, she combines a solid academic background with practical experience in both sectors.
About Eton Pharmaceuticals
Eton Pharmaceuticals is a forward-thinking company devoted to creating and marketing treatments for rare diseases. They currently offer a range of rare disease products, including ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. Additionally, Eton is advancing several product candidates, including ET-400, ET-600, and ZENEO® hydrocortisone autoinjector, showcasing their commitment to improving patient outcomes.
Frequently Asked Questions
Who is Ipek Erdogan-Trinkaus?
Ipek Erdogan-Trinkaus is the newly appointed Chief Commercial Officer at Eton Pharmaceuticals, bringing extensive experience in pharmaceutical sales and marketing.
What experience does Ms. Erdogan-Trinkaus have?
Ms. Erdogan-Trinkaus has significant experience in pediatric endocrinology and previously held leadership roles at Tolmar Pharmaceuticals and other companies.
What products is Eton Pharmaceuticals known for?
Eton Pharmaceuticals is known for developing treatments like ALKINDI SPRINKLE®, PKU GOLIKE®, and others aimed at managing rare diseases.
What are the upcoming products Eton is launching?
The company anticipates launching Increlex and ET-400 in the near future, marking significant advancements in their therapeutic offerings.
How can I contact Eton Pharmaceuticals for investor inquiries?
For investor relations, you may contact Lisa M. Wilson at In-Site Communications via phone at 212-452-2793 or email at lwilson@insitecony.com.
